I work as a research assistant in Hal Drakesmith's group where I primarily consider hepcidin, the iron regulatory hormone, from a global health perspective. We have explored its potential for use as a diagnostic of iron deficiency in a number of environmentally and physiologically different populations. I also contribute to work within the Drakesmith lab that investigates hepcidin and iron status in the context of inflammation and infection.
I addition to this, I have supported the work of Dr Noémi Roy in her development of the Oxford Red Cell Panel, a diagnostic sequencing service within the John Radcliffe that screens for mutations linked to rare congenital anaemias. I continue to work in this area through exploration of potentially disease-causing variants that have been identified by whole genome sequencing.
I hold an MBioch from Oxford University, graduating in 2012 following a research project relating to localisation of mRNA in the neurons of fruit flies, and began work in the Drakesmith lab in 2014.
Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection.
Frost JN. et al, (2021), Med (N Y), 2, 164 - 179.e12
The p.H63D allele of the HFE gene protects against low iron stores in Sri Lanka.
Allen A. et al, (2019), Blood Cells Mol Dis, 76, 72 - 77
Serum hepcidin potentially identifies iron deficiency in survivors of critical illness at the time of hospital discharge.
Shah A. et al, (2019), Br J Haematol, 184, 279 - 281
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.
Pasricha S-R. et al, (2017), Nat Commun, 8
EARLY LESSONS FROM WHOLE-GENOME SEQUENCING IN THE CLINICAL DIAGNOSIS OF RARE INHERITED ANAEMIAS
Roy N. et al, (2017)